Research Topics
Genomes and GenesSpecies | J JankovicSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Diagnosis and treatment of complications related to deep brain stimulation hardwareJosé Fidel Baizabal Carvallo
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
Mov Disord 26:1398-406. 2011..Our aim is to provide a guide for clinicians and medical staff involved in the treatment of patients with deep brain stimulation for rapid recognition and efficient management of these complications...
Evidence-based review of patient-reported outcomes with botulinum toxin type AJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Neuropharmacol 27:234-44. 2004..These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent...
Essential tremor: a heterogenous disorderJoseph Jankovic
Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 17:638-44. 2002
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's diseaseJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Smith 1801, Houston, TX 77030, USA
Parkinsonism Relat Disord 8:271-6. 2002....
Levodopa strengths and weaknessesJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 58:S19-32. 2002..However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management...
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystoniaJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
Neurology 67:2233-5. 2006..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
Prevalence of cervical dystonia and spasmodic torticollis in the United States general populationJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Parkinsonism Relat Disord 13:411-6. 2007..To examine the prevalence of cervical dystonia (CD) in the US population...
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson diseaseJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Arch Neurol 64:676-82. 2007..To assess the response to the rotigotine transdermal system (Neupro; Schwarz Pharma Ltd, Monheim, Germany), a nonergolinic dopamine agonist, in patients with early Parkinson disease...
Botulinum toxin for the treatment of cervical dystoniaR Tintner
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Expert Opin Pharmacother 2:1985-94. 2001....
Treatment of cervical dystonia with botulinum toxinJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 19:S109-15. 2004..Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long-term complications of CD, such as contractures and radiculopathy, have been largely eliminated...
Exploring the relationship between essential tremor and Parkinson's diseaseJoohi Shahed
Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, TX, USA
Parkinsonism Relat Disord 13:67-76. 2007..We examine here the evidence for and against an association between ET and PD, and critically review data supporting the notion that a subset of ET patients is predisposed to developing PD...
An update on the treatment of Parkinson's diseaseJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, The Smith Tower, Suite 1801, 6550 Fannin, Houston, TX 77030, USA
Mt Sinai J Med 73:682-9. 2006....
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 60:1186-8. 2003..004). The current preparation decreased the risk of antibody formation by a factor of six. The authors conclude that the low risk of antibody formation after current BTX type A treatment is related to lower protein load...
Essential tremor among childrenJoseph Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin St, Suite 1801, Houston, TX 77030, USA
Pediatrics 114:1203-5. 2004..To characterize the clinical and therapeutic aspects of essential tremor (ET) among children...
Tourette's syndrome and the lawJoseph Jankovic
Parkinson s Disease Center and Movement Diorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
J Neuropsychiatry Clin Neurosci 18:86-95. 2006..The medical-legal community must learn to recognize the vulnerability of this patient population to potential mistreatment by the courts of justice...
Genetic mouse models of essential tremor: are they essential?Joseph Jankovic
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
J Clin Invest 115:584-6. 2005....
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestationsJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Mov Disord 20:S11-6. 2005..Recognition of the full spectrum of clinical phenomenology of levodopa-related motor complications is essential for their treatment and prevention...
Botulinum toxin in clinical practiceJ Jankovic
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
J Neurol Neurosurg Psychiatry 75:951-7. 2004..Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications...
Searching for a relationship between manganese and welding and Parkinson's diseaseJoseph Jankovic
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 64:2021-8. 2005..The controversy has stimulated this review, the primary aim of which is to critically and objectively examine the evidence or lack of evidence for a relationship among welding, manganese, parkinsonism, and PD...
Botulinum toxin therapy for cervical dystoniaJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurotox Res 9:145-8. 2006..This review provides and update on the treatment of CD with BoNT type A (BOTOX, Dysport, Xeomin and BoNT type B (Myobloc, NeuroBloc...
Psychogenic tremor: long-term outcomeJoseph Jankovic
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
CNS Spectr 11:501-8. 2006..Psychogenic movement disorders are increasingly encountered in specialized clinics, and represent approximately 15% of all patients evaluated in the Baylor College of Medicine Movement Disorders Clinic...
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disordersJoseph Jankovic
Baylor College of Medicine, Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Houston, TX, USA
Expert Rev Neurother 11:1509-23. 2011....
Functional decline in Parkinson diseaseJ Jankovic
Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Arch Neurol 58:1611-5. 2001..To determine the overall rate of functional decline and to assess the progression of different signs of Parkinson disease (PD)...
Diagnosis and treatment of psychogenic parkinsonismJoseph Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, The Smith Tower, Suite 1801 6550 Fannin Houston, TX 77030, USA
J Neurol Neurosurg Psychiatry 82:1300-3. 2011....
Re-emergent tremor of Parkinson's diseaseJ Jankovic
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
J Neurol Neurosurg Psychiatry 67:646-50. 1999..It is postulated that one type of postural tremor in Parkinson's disease represents a rest tremor that re-emerges after a variable delay while maintaining posture, hence "re-emergent tremor"...
The evolution of diagnosis in early Parkinson disease. Parkinson Study GroupJ Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Tex 77030, USA
Arch Neurol 57:369-72. 2000..Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD...
Levodopa-induced dyskinesias treated by pallidotomyJ Jankovic
Baylor College of Medicine, Dir of Parkinson s Disease Ctr and Movement Disorders Ctr, 6550 Fannin 1801, Houston, TX 77030, USA
J Neurol Sci 167:62-7. 1999..We conclude that pallidotomy is an effective and safe procedure in the treatment of medically intractable LID...
Transcutaneous electrical stimulation (TENS) for psychogenic movement disordersJoseph Ferrara
Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
J Neuropsychiatry Clin Neurosci 23:141-8. 2011..Although the tingling sensation produced by TENS makes it poorly suited for a controlled clinical trial, the device has a favorable side-effect profile and is an acceptable palliative treatment for a subset of PMD patients...
Tourette's syndrome in adultsJoseph Jankovic
Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 25:2171-5. 2010..In addition, adults with TS are more likely to exhibit substance abuse and mood disorders compared with children with TS...
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasmJ Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
Eur J Neurol 16:14-8. 2009..1% Xeomin and 4.5% Botox). Conclusion: Clinical evidence to date suggests that Xeomin is an effective treatment for blepharospasm that does not differ from Botox in terms of its potency, duration of effect or adverse reaction profile...
A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndromeJ Jankovic
Baylor College of Medicine, Department of Neurology, Houston, TX 77030, USA
J Neurol Neurosurg Psychiatry 81:70-3. 2010..To investigate the effects of topiramate on Tourette syndrome (TS)...
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's diseaseJoseph Ferrara
Parkinson Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
J Neurol Neurosurg Psychiatry 81:315-9. 2010..In this study, we evaluate the effect of STN DBS on quality of life using the QLS(M), a modular questionnaire in which satisfaction scores for each item are weighted in light of patient-rated importance...
Botulinum toxin: historical perspective and potential new indicationsJ Jankovic
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Muscle Nerve Suppl 6:S129-45. 1997..Patient selection and the proper choice of dose and administration site are the most important determinants of a favorable response to BTX treatment...
Parkinson's disease and movement disorders: moving forwardJoseph Jankovic
Parkinson's Disease and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Lancet Neurol 7:9-11. 2008
Parkinson's disease: clinical features and diagnosisJ Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030 3498, USA
J Neurol Neurosurg Psychiatry 79:368-76. 2008..This review describes the clinical characteristics of PD with emphasis on those features that differentiate the disease from other parkinsonian disorders...
Treatment of dystoniaJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Lancet Neurol 5:864-72. 2006....
Dystonia and parkinsonismJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Parkinsonism Relat Disord 8:109-21. 2001....
Peripherally induced movement disordersJoseph Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
Neurol Clin 27:821-32, vii. 2009..The pathophysiology of these disorders is reviewed...
Movement disorders in musiciansJoseph Jankovic
Parkinson s Disease Center, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 23:1957-65. 2008....
Treatment of hyperkinetic movement disordersJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
Lancet Neurol 8:844-56. 2009..Finally, success with surgical approaches, particularly deep brain stimulation in patients with Parkinson's disease who have levodopa-induced dyskinesias, has been extended to the treatment of many hyperkinetic movement disorders...
Preclinical biomarkers of Parkinson diseaseYuncheng Wu
Department of Neurology, Shanghai First People s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Arch Neurol 68:22-30. 2011....
Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson diseaseH Deng
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 65:651-2. 2005
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injuryW Le
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
J Neurochem 73:2218-21. 1999..This study suggests that Nurr1 may play an important role in maintaining mature mesencephalic dopaminergic neuron function and that a defect in Nurr1 may increase susceptibility to SN injury...
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's diseaseM K York
Baylor College of Medicine, Department of Neurology, 6501 Fannin, NB302, Houston, Texas 77030, USA
J Neurol Neurosurg Psychiatry 79:789-95. 2008..We investigated the cognitive and psychiatric outcome 6 months after bilateral subthalamic nucleus deep brain stimulation (DBS) for the treatment of Parkinson's disease (PD) using a disease control group...
The impact of depressive symptoms in early Parkinson diseaseB Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Neurology 69:342-7. 2007..No previous study has systematically examined the impact of depressive symptoms in early, untreated PD...
Autonomic function after botulinum toxin type A or B: a double-blind, randomized trialR Tintner
Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Neurology 65:765-7. 2005..Patients treated with BTX-B had less saliva production (p < 0.01) and greater severity of constipation (p = 0.037) than those treated with BTX-A, but did not differ in other tests of autonomic functions...
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controlsW Ondo
Department of Neurlogy, Baylor College of Medicine, Houston, Texas, USA
Arch Neurol 57:1464-9. 2000..Progressive supranuclear palsy (PSP) is a neurodegenerative disorder that is frequently mistaken for Parkinson's disease (PD) in its early stages...
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD M Simpson
Department of Neurology, Mount Sinai Medical Center, New York, NY, USA
Neurology 70:1699-706. 2008..To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders...
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotectionW D Le
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
J Neural Transm 107:1165-73. 2000..5 cells. These results indicate that pramipexole's neuroprotective effects are likely associated with its antioxidant property independent of D2/D3 receptor activation...
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disordersChristopher Kenney
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 22:193-7. 2007..6%), and akathisia (7.6%). Comparison of log-likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long-term treatment of hyperkinetic movement disorders...
Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's diseaseA M Strutt
Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Eur J Neurol 19:121-7. 2012..Subthalamic nucleus deep brain stimulation (STN-DBS) has been shown to have beneficial effects on the motor features of Parkinson's disease (PD), but its impact on non-motor symptoms, most notably mood, has not been fully explored...
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndromeH Deng
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX 77030, USA
Acta Neurol Scand 114:400-2. 2006..To determine whether variants in the Slit and Trk-like 1 gene (SLITRK1) are present in American Caucasian population of patients with Tourette syndrome (TS)...
Topiramate in essential tremor: a double-blind, placebo-controlled trialW G Ondo
Baylor College of Medicine, Houston, TX 77030, USA
Neurology 66:672-7. 2006..Additional therapies are required for patients with an inadequate response or intolerable side effects. In small trials, topiramate appeared to be beneficial in essential tremor...
Maternal inheritance and mitochondrial DNA variants in familial Parkinson's diseaseDavid K Simon
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
BMC Med Genet 11:53. 2010..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD...
Are dopamine receptor agonists neuroprotective in Parkinson's disease?W D Le
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Drugs Aging 18:389-96. 2001....
Daytime sleepiness and other sleep disorders in Parkinson's diseaseW G Ondo
Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Neurology 57:1392-6. 2001..PD is associated with a variety of sleep problems. The dopamine agonists (DA) pramipexole and ropinirole were recently implicated in causing "sleep attacks" and motor vehicle accidents...
Thalamic deep brain stimulation: effects on the nontarget limbsW Ondo
Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
Mov Disord 16:1137-42. 2001..We conclude that VIM DBS may mildly improve ipsilateral ET, and that concerns about meaningful ipsilateral tremor augmentation after device deactivation are not warranted...
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's diseaseJ Jankovic
Department of Neurology, Parkinson Disease Research Lab, Baylor College of Medicine, Houston, TX 77030, USA
Prog Neurobiol 77:128-38. 2005..All these studies suggest that Nurr1 is not only essential in the development of mensencephalic dopaminergic neurons and maintenance of their functions, but it may also play a role in the pathogenesis of PD...
The effect of deep brain stimulation on quality of life in movement disordersA Diamond
Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Street, Suite 1801, Houston, TX 77030, USA
J Neurol Neurosurg Psychiatry 76:1188-93. 2005..We systematically and critically reviewed the literature on the effects of DBS on HRQoL in PD, ET, dystonia, and cerebellar outflow tremor related to multiple sclerosis...
Dystonia in corticobasal degenerationZ Vanek
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 16:252-7. 2001..Axial or leg dystonia, without significant involvement of an arm, is rare. There is no effective treatment for this relentless disorder, except for temporary relief of dystonia and pain, with local botulinum toxin injections...
Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysisM K York
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Acta Neurochir (Wien) 149:857-66; discussion 866. 2007..We investigated retrospectively the short and long-term motor and cognitive functioning of staged bilateral pallidotomy using motor testing and a comprehensive neuropsychological battery before and after each procedure...
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson diseaseR L Watts
Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233 0017, USA
Neurology 68:272-6. 2007....
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's diseaseP Y Xu
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 58:881-4. 2002..To determine whether the Nurr1 gene, which is critical for the development and maintenance of nigral dopaminergic neurons, is a risk factor associated with PD...
Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and applicationJ K Krauss
Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
Neurosurgery 48:535-41; discussion 541-3. 2001..To rationalize the technique and reduce the costs associated with chronic deep brain stimulation of the thalamus for treatment of refractory tremor...
Thalamic deep brain stimulation: comparison between unilateral and bilateral placementW Ondo
Department of Neurology, Baylor College of Medicine, 6550 Fannin Dr, Suite 1801, Houston, TX 77030, USA
Arch Neurol 58:218-22. 2001..There are, however, relatively little data concerning bilateral thalamic DBS and no thorough comparisons between the 2 methods...
Tetrabenazine in the treatment of hyperkinetic movement disordersChristopher Kenney
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
Expert Rev Neurother 6:7-17. 2006....
Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson diseasePeter A LeWitt
Department of Neurology, Wayne State University School of Medicine, and Henry Ford Hospital Franklin Pointe Medical Center, 26400 West 12 Mile Road, Southfield, MI 48034, USA
Clin Neuropharmacol 30:256-65. 2007....
Comparison of thalamotomy and pallidotomy for the treatment of dystoniaD Yoshor
Department of Neurosurgery, Baylor College of Medicine, Houston, Texas 77030, USA
Neurosurgery 48:818-24; discussion 824-6. 2001..In this study, we compare our results using thalamotomy and pallidotomy to treat patients with different forms of dystonia, and we discuss our results in the context of other published series...
Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndromeChristopher Kenney
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
Expert Opin Pharmacother 8:1329-35. 2007..Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties...
Long-term botulinum toxin efficacy, safety, and immunogenicityNicte I Mejia
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 20:592-7. 2005..Except for 1 patient, the 4 Ab-positive and the 2 clinical nonresponders are being treated with BTX-B. This longest reported follow-up of BTX injections confirms the long-term efficacy and safety of this treatment...
Atomoxetine for freezing of gait in Parkinson diseaseJoseph Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, United States
J Neurol Sci 284:177-8. 2009..Further studies in a larger population of patients with FoG are needed to determine whether atomoxetine is a useful drug in the treatment of this, often disabling, feature of PD...
A study of chorea after tetrabenazine withdrawal in patients with Huntington diseaseSamuel Frank
Department of Neurology, Boston University School of Medicine, Boston, MA, USA
Clin Neuropharmacol 31:127-33. 2008..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutationsHao Deng
Department of Neurology, Baylor College of Medicine, Houston, Tex 77030, USA
Arch Neurol 63:273-7. 2006..Mutations in the parkin gene (PRKN) cause autosomal recessive early-onset Parkinson disease (EOPD)...
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/ABehzod Z Dolimbek
Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Mol Immunol 44:1029-41. 2007..The molecular and clinical implications of these findings are discussed...
Genetic study of an American family with DYT3 dystonia (lubag)Hao Deng
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurosci Lett 448:180-3. 2008..In contrast, TAF1 and CXCR3 gene expression in peripheral blood lymphocytes is not a suitable surrogate disease marker for DYT3...
GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbiditiesJ Shahed
Parkinson's Disease Center, and Movement Disorders Clinic, Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
Neurology 68:159-60. 2007
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocolW G Ondo
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Am J Psychiatry 156:1279-81. 1999..Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tetrabenazine for tardive dyskinesia...
Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee educationO R Adam
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurology 73:e50-2. 2009..Such data might provide insights which augment patient care, and may be instructive regarding medical education, since patient-related telephone calls are often addressed by physicians-in-training...
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trialW G Ondo
Baylor College of Medicine, Houston, TX 77030, USA
J Neurol Neurosurg Psychiatry 76:1636-9. 2005..The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions...
Hearing impairment in essential tremorW G Ondo
Department of Neurology, Baylor College of Medicine, Houston, USA
Neurology 61:1093-7. 2003..To assess hearing in patients with essential tremor (ET) vs patients with Parkinson disease (PD) and normal controls...
Tetrabenazine treatment for Huntington's disease-associated choreaWilliam G Ondo
Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Neuropharmacol 25:300-2. 2002..TBZ was well tolerated and resulted in a significant improvement in modified AIMS scores in HD patients. These results support the use of TBZ for chorea in patients with HD...
The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremorAlan Diamond
Department of Neurology, Baylor College of Medicine, United States
J Neurol Sci 260:199-203. 2007..9% (p=0.008) and upper extremity 92.5% (p=0.008) TRS subscore. Functional improvement was noted with pouring liquids. Our findings provide support that STN DBS is an effective treatment of tremor associated with PD...
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatmentM Zouhair Atassi
Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Mol Immunol 45:3878-88. 2008..These regions afford candidates for epitope-specific manipulation of anti-toxin immune responses...
Medical management of levodopa-associated motor complications in patients with Parkinson's diseaseJoseph Jankovic
Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
CNS Drugs 21:677-92. 2007....
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's diseaseJames K Sheffield
Department of Neurology, Baylor College of Medicine, Parkinson s Disease Center and Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
Expert Rev Neurother 7:637-47. 2007....
Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trialJoseph M Ferrara
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
J Neurol Sci 285:195-7. 2009..Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness...
Premonitory sensory phenomenon in Tourette's syndromeCarolyn Kwak
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
Mov Disord 18:1530-3. 2003..We conclude that premonitory sensations are an important aspect of motor tics and some patients perceive motor tics as a voluntary movement in response to an involuntary sensation...
Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease familiesHao Deng
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Neurosci Lett 430:18-22. 2008..The results may provide new insights into the cause and diagnosis of PD and have implications for genetic counseling...
Exploring the relationship between Parkinson disease and restless legs syndromeWilliam G Ondo
Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030
Arch Neurol 59:421-4. 2002..Restless legs syndrome (RLS) and Parkinson disease (PD) are common neurological conditions that respond to dopaminergic therapy. To our knowledge, the relationship between the two has not been thoroughly explored...
A peptide-based immunoassay for antibodies against botulinum neurotoxin AM Zouhair Atassi
Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
J Mol Recognit 20:15-21. 2007....
An open-label pilot study of levetiracetam for essential tremorWilliam G Ondo
Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA
Clin Neuropharmacol 27:274-7. 2004..Adverse events included dizziness (n=2), sedation (n=1), and nervousness (n=1). Levetiracetam was well tolerated but failed to improve tremor consistently in this small trial...
Long-term evaluation of deep brain stimulation of the thalamusRajesh Pahwa
Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
J Neurosurg 104:506-12. 2006..The aim of this study was to evaluate the long-term safety and efficacy of DBS of the ventralis intermedius nucleus (VIM) of the thalamus for PD and ET...
Dopamine agonists in Parkinson's diseaseRon Tintner
Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, 1801, Houston, Texas 77030, USA
Expert Opin Investig Drugs 12:1803-20. 2003..The adverse effects of DAs are similar to those experienced with LD, except that the ergot agents are associated with a small risk of tissue fibrosis not noted with the non-ergot DAs...
Subthalamic deep brain stimulation in patients with a previous pallidotomyWilliam G Ondo
Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
Mov Disord 21:1252-4. 2006..This may be partially due to a selection bias, but it may also indicate that prior pallidotomy is a negative predictor of outcome of STN DBS and should be considered in patient selection...
Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson DiseaseRon Tintner
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, USA
Arch Neurol 62:1290-5. 2005..We also review evidence that the risk of this complication is substantially lower with the newer nonergot dopamine agonists...
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategyC Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 94, One Gustave L Levy Place, New York, NY 10029, USA
Mov Disord 20:S3-10. 2005..If implemented early in the course of the disease, such treatments, if found effective, may not only alter the natural progression of the disease but may also delay or minimize motor and nonmotor complications associated with levodopa...
Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson diseaseChuantao Jiang
Parkinson Disease Research Lab, Department of Neurology, Baylor College of Medicine, Houston, TX, USA
Clin Neuropharmacol 27:63-73. 2004....
Mutations in NR4A2 associated with familial Parkinson diseaseWei Dong LE
Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
Nat Genet 33:85-9. 2003..Additionally, mutations in NR4A2 affect transcription of the gene encoding tyrosine hydroxylase. These data suggest that mutations in NR4A2 can cause dopaminergic dysfunction, associated with Parkinson disease...
Genetics of essential tremorHao Deng
Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
Brain 130:1456-64. 2007..Further analyses of these genetic abnormalities may lead to the identification of causative mutations and a better understanding of the molecular mechanisms in this common movement disorder...
